CD274 and head and neck squamous cell carcinoma: Immune checkpoint inhibitors (ICIs) pembrolizumab (MK-3475) and nivolumab (BMS-936558), which target the programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) pathway, were approved for HNSCC by the US Food and Drug Administration (FDA).